Review



mouse anti‐human msln mn‐1  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bio X Cell mouse anti‐human msln mn‐1
    Mouse Anti‐Human Msln Mn‐1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/mouse+anti+human+msln+mn+1/pmc11646052-52-9-13
    Average 90 stars, based on 1 article reviews
    mouse anti‐human msln mn‐1 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Membrane:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Construct:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Mutagenesis:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Variant Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Activity Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Stable Transfection:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Transfection:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Plasmid Preparation:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Expressing:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Flow Cytometry:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Injection:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Concentration Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Enzyme-linked Immunosorbent Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Transduction:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Clone Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Isolation:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Western Blot:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Marker:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Over Expression:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Blocking Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Fluorescence:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Microscopy:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Labeling:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Sequencing:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Quantitation Assay:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Negative Control:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Quantitative Proteomics:

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization
    Article Snippet: Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.Proteins were separated by SDS‐PAGE, transferred to PVDF membrane, and blocked in 5% milk solution.. The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).



    Similar Products

    mouse anti human msln igg  (Vector Laboratories)
    86
    Vector Laboratories mouse anti human msln igg
    Mouse Anti Human Msln Igg, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/us10633441-1037-8-13
    Average 86 stars, based on 1 article reviews
    mouse anti human msln igg - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    mouse anti‐human msln mn‐1  (Bio X Cell)
    90
    Bio X Cell mouse anti‐human msln mn‐1
    Mouse Anti‐Human Msln Mn‐1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/mouse+anti+human+msln+mn+1/pmc11646052-52-9-13
    Average 90 stars, based on 1 article reviews
    mouse anti‐human msln mn‐1 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    msln mouse human msln  (Bio X Cell)
    92
    Bio X Cell msln mouse human msln
    Experimental design. (A) Schema depicting experimental plan for testing pro‐tumorigenicity of protein products of <t>MSLN</t> gene. Red bar shows MPF protein, which is expected to be secreted. Blue bar shows MSLN protein. Lighter blue indicates residues C‐terminal to the GPI anchor which is required for membrane‐bound MSLN. Constructs missing the GPI‐anchor are expected to be secreted‐only. Darker blue residues indicate those which may contribute to sMSLN. Y318A point mutation ablates MSLN interaction with MUC‐16. (B) Schematic showing each MSLN variant complemented into KO cells.
    Msln Mouse Human Msln, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/InVivoMAb+anti-mouse+human+Mac-2/pmc11646052-70-9-12
    Average 92 stars, based on 1 article reviews
    msln mouse human msln - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    mouse anti human msln monoclonal antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mouse anti human msln monoclonal antibody
    Immunohistochemical and Immunofluorescence analysis of <t>MSLN</t> and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x
    Mouse Anti Human Msln Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/Mesothelin+Antibody/pmc11411782-127-32-38
    Average 93 stars, based on 1 article reviews
    mouse anti human msln monoclonal antibody - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    antibody mouse anti-human,mouse,rat – clone: msln/2131  (Fisher Scientific)
    90
    Fisher Scientific antibody mouse anti-human,mouse,rat – clone: msln/2131
    Immunohistochemical and Immunofluorescence analysis of <t>MSLN</t> and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x
    Antibody Mouse Anti Human,Mouse,Rat – Clone: Msln/2131, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/antibody+mouse+anti+human+mouse+rat+++clone++msln+2131/pmc10666227__ao3c04492_si_001-77-8-10
    Average 90 stars, based on 1 article reviews
    antibody mouse anti-human,mouse,rat – clone: msln/2131 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse anti human msln  (R&D Systems)
    90
    R&D Systems mouse anti human msln
    Immunohistochemical and Immunofluorescence analysis of <t>MSLN</t> and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x
    Mouse Anti Human Msln, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/Mouse+anti-Human+IgG2+Fc+Secondary+Antibody+(3C7)/pm33373818-40-24-27
    Average 90 stars, based on 1 article reviews
    mouse anti human msln - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse anti-human msln antibody  (Rockland Immunochemicals)
    90
    Rockland Immunochemicals mouse anti-human msln antibody
    Immunohistochemical and Immunofluorescence analysis of <t>MSLN</t> and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x
    Mouse Anti Human Msln Antibody, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/ANTI-HUMAN+IL-17A+(MOUSE)+BIOTIN+CONJUGA/pmc04936933-153-15-19
    Average 90 stars, based on 1 article reviews
    mouse anti-human msln antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse anti-human msln antibody rockland immunochemicals  (Rockland Immunochemicals)
    90
    Rockland Immunochemicals mouse anti-human msln antibody rockland immunochemicals
    Immunohistochemical and Immunofluorescence analysis of <t>MSLN</t> and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x
    Mouse Anti Human Msln Antibody Rockland Immunochemicals, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/msln+mouse+human+msln/mouse+anti+human+msln+antibody+rockland+immunochemicals/10__1158_slash_1535___7163__mct___15___0863-67-15-19
    Average 90 stars, based on 1 article reviews
    mouse anti-human msln antibody rockland immunochemicals - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Experimental design. (A) Schema depicting experimental plan for testing pro‐tumorigenicity of protein products of MSLN gene. Red bar shows MPF protein, which is expected to be secreted. Blue bar shows MSLN protein. Lighter blue indicates residues C‐terminal to the GPI anchor which is required for membrane‐bound MSLN. Constructs missing the GPI‐anchor are expected to be secreted‐only. Darker blue residues indicate those which may contribute to sMSLN. Y318A point mutation ablates MSLN interaction with MUC‐16. (B) Schematic showing each MSLN variant complemented into KO cells.

    Journal: The FASEB Journal

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization

    doi: 10.1096/fj.202400446R

    Figure Lengend Snippet: Experimental design. (A) Schema depicting experimental plan for testing pro‐tumorigenicity of protein products of MSLN gene. Red bar shows MPF protein, which is expected to be secreted. Blue bar shows MSLN protein. Lighter blue indicates residues C‐terminal to the GPI anchor which is required for membrane‐bound MSLN. Constructs missing the GPI‐anchor are expected to be secreted‐only. Darker blue residues indicate those which may contribute to sMSLN. Y318A point mutation ablates MSLN interaction with MUC‐16. (B) Schematic showing each MSLN variant complemented into KO cells.

    Article Snippet: The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Techniques: Membrane, Construct, Mutagenesis, Variant Assay

    Assessing the activity of MPF versus membrane‐bound mature MSLN. KLM1 MSLN KO cells were stably transfected with empty vector (KO+vec), MSLNf, or MPFf. (A) KLM1 derivative cells were assessed for membrane‐bound MSLN expression by flow cytometry. (B) Growth rate of the cell lines on tissue culture plastic was measured. There was no significant difference between the groups. (C–F) Cell lines were injected IP into nude mice and allowed to grow for ~6 weeks. (C) Total burden of peritoneal tumor was measured, *** p < .001. (D, E) MSLN and MPF concentration in tumor lysate was measured by ELISA assay. (F) Tumor burden of co‐injected +MSLNf and +MPFf cells was assessed, * p < .05; ns, not significant.

    Journal: The FASEB Journal

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization

    doi: 10.1096/fj.202400446R

    Figure Lengend Snippet: Assessing the activity of MPF versus membrane‐bound mature MSLN. KLM1 MSLN KO cells were stably transfected with empty vector (KO+vec), MSLNf, or MPFf. (A) KLM1 derivative cells were assessed for membrane‐bound MSLN expression by flow cytometry. (B) Growth rate of the cell lines on tissue culture plastic was measured. There was no significant difference between the groups. (C–F) Cell lines were injected IP into nude mice and allowed to grow for ~6 weeks. (C) Total burden of peritoneal tumor was measured, *** p < .001. (D, E) MSLN and MPF concentration in tumor lysate was measured by ELISA assay. (F) Tumor burden of co‐injected +MSLNf and +MPFf cells was assessed, * p < .05; ns, not significant.

    Article Snippet: The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Techniques: Activity Assay, Membrane, Stable Transfection, Transfection, Plasmid Preparation, Expressing, Flow Cytometry, Injection, Concentration Assay, Enzyme-linked Immunosorbent Assay

    Assessing the activity of secreted‐only MSLN in KO cells. (A) Schema depicting truncation mutant (Δ591) to remove the GPI anchoring site and prevent membrane association of mature MSLN. KLM1 MSLN KO cells were stably transduced with WT and Y318A (Mu) Δ591 expression vectors and single cell clones were isolated. (B) Immunoblot of Δ591 clones to assess for MSLN expression. (C) Conditioned medium of Δ591 clones plated at equal density was assayed for MSLN concentration by ELISA. (D) Representative experiment showing growth rate of the KO+ Δ591 cell lines on tissue culture plastic as measured by counting cell number in triplicate wells. (E) Cells were suspended in soft agar and colonies were counted after ~3 weeks. Figure depicts raw data of triplicate wells (marker) in each experiment (bar). ** p < .01 or *** p < .001 indicate statistically significant difference as compared to parent for at least 2 of 3 experiments (in same direction of change). (F, G) Cell lines were injected IP into nude mice and allowed to grow for ~6 weeks. (F) Tumors were lysed and MSLN expression was assayed by immunoblot. (G) Total burden of peritoneal tumor dissected from the mouse abdominal cavity, * p < .05. Each point represents one animal. Results were confirmed by repeat using other Δ591WT and Δ591Mu clones. (H) MUC‐16 surface expression was assessed by flow cytometry. Left— Representative tracing. Right— Summary of geometric means in relation to Parent over multiple experiments.

    Journal: The FASEB Journal

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization

    doi: 10.1096/fj.202400446R

    Figure Lengend Snippet: Assessing the activity of secreted‐only MSLN in KO cells. (A) Schema depicting truncation mutant (Δ591) to remove the GPI anchoring site and prevent membrane association of mature MSLN. KLM1 MSLN KO cells were stably transduced with WT and Y318A (Mu) Δ591 expression vectors and single cell clones were isolated. (B) Immunoblot of Δ591 clones to assess for MSLN expression. (C) Conditioned medium of Δ591 clones plated at equal density was assayed for MSLN concentration by ELISA. (D) Representative experiment showing growth rate of the KO+ Δ591 cell lines on tissue culture plastic as measured by counting cell number in triplicate wells. (E) Cells were suspended in soft agar and colonies were counted after ~3 weeks. Figure depicts raw data of triplicate wells (marker) in each experiment (bar). ** p < .01 or *** p < .001 indicate statistically significant difference as compared to parent for at least 2 of 3 experiments (in same direction of change). (F, G) Cell lines were injected IP into nude mice and allowed to grow for ~6 weeks. (F) Tumors were lysed and MSLN expression was assayed by immunoblot. (G) Total burden of peritoneal tumor dissected from the mouse abdominal cavity, * p < .05. Each point represents one animal. Results were confirmed by repeat using other Δ591WT and Δ591Mu clones. (H) MUC‐16 surface expression was assessed by flow cytometry. Left— Representative tracing. Right— Summary of geometric means in relation to Parent over multiple experiments.

    Article Snippet: The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Techniques: Activity Assay, Mutagenesis, Membrane, Stable Transfection, Transduction, Expressing, Clone Assay, Isolation, Western Blot, Concentration Assay, Enzyme-linked Immunosorbent Assay, Marker, Injection, Flow Cytometry

    Overexpression of sMSLN inhibits the pro‐tumorigenic activity of cells expressing membrane‐bound MSLN. (A) Proposed model showing how sMSLN might block cell–cell association by interfering with interactions between MUC‐16 and membrane‐bound MSLN. (B–H) KLM1 cells were stably transduced with Δ591 MSLN expression vectors and pooled cells were used for experiments. (B) Expression of MSLN in conditioned medium as detected by ELISA. (C) Representative experiment showing growth rate of the cell lines on tissue culture plastic as measured by counting cell number in triplicate wells for each time point. No significant difference in growth was observed. (D–F) Cell lines were injected IP into nude mice and allowed to grow for ~6 weeks, * p < .05; *** p < .001; **** p < .0001; ns, not significant. (D) Total burden of peritoneal tumor dissected from the mouse abdominal cavity. Each point represents one animal. (E) Tumors were lysed and MSLN expression was assayed by immunoblot. Each lane is lysate from one mouse tumor. (F) Serum MSLN expression was assayed by ELISA. (G, H) Indicated cells were tagged with CellTracker dye and visualized by fluorescence microscopy. Representative images of multiple replicates with four to eight fields imaged per replicate. (G) Labeled cells were plated at equal density onto low adherence plates for 24 h before visualization. (H) Labeled cells were injected IP into nude mice. Mice were euthanized 4 h later and peritoneal lavage fluid was collected for visualization.

    Journal: The FASEB Journal

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization

    doi: 10.1096/fj.202400446R

    Figure Lengend Snippet: Overexpression of sMSLN inhibits the pro‐tumorigenic activity of cells expressing membrane‐bound MSLN. (A) Proposed model showing how sMSLN might block cell–cell association by interfering with interactions between MUC‐16 and membrane‐bound MSLN. (B–H) KLM1 cells were stably transduced with Δ591 MSLN expression vectors and pooled cells were used for experiments. (B) Expression of MSLN in conditioned medium as detected by ELISA. (C) Representative experiment showing growth rate of the cell lines on tissue culture plastic as measured by counting cell number in triplicate wells for each time point. No significant difference in growth was observed. (D–F) Cell lines were injected IP into nude mice and allowed to grow for ~6 weeks, * p < .05; *** p < .001; **** p < .0001; ns, not significant. (D) Total burden of peritoneal tumor dissected from the mouse abdominal cavity. Each point represents one animal. (E) Tumors were lysed and MSLN expression was assayed by immunoblot. Each lane is lysate from one mouse tumor. (F) Serum MSLN expression was assayed by ELISA. (G, H) Indicated cells were tagged with CellTracker dye and visualized by fluorescence microscopy. Representative images of multiple replicates with four to eight fields imaged per replicate. (G) Labeled cells were plated at equal density onto low adherence plates for 24 h before visualization. (H) Labeled cells were injected IP into nude mice. Mice were euthanized 4 h later and peritoneal lavage fluid was collected for visualization.

    Article Snippet: The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Techniques: Over Expression, Activity Assay, Expressing, Membrane, Blocking Assay, Stable Transfection, Transduction, Enzyme-linked Immunosorbent Assay, Injection, Western Blot, Fluorescence, Microscopy, Labeling

    Excess of sMSLN prevents cell clustering. (A) Schema showing method used to produce MSLN‐containing CM. Mock cells underwent transient transfection with Cas9 vector like MSLN KO cells, but no gRNA was included, so they retain endogenous MSLN expression (MSLN+). Transduction of KO cells with full‐length MSLN WT or Y318A expression construct produces the KO+WT and KO+Mu cell lines which overexpress MSLN (MSLN++). (B) ELISA to assess MSLN concentration of CM from equal numbers of cells plated for each type. (C) Cells were tagged with CellTracker dye then plated at equal density onto low adherence plates for 24 h before visualization by fluorescence microscopy. Representative images of multiple replicates with 4–8 fields imaged per replicate. (D) Schema for treatment of KLM1 and T3M4 KO cells with CM prior to RNA harvest. (E) PCA plots following RNA deep‐sequencing of CM‐treated KO cells. (F) Quantitation and directionality of GSEA pathway changes in KO cells treated with KO CM (negative control) as compared to MSLN‐containing CMs.

    Journal: The FASEB Journal

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization

    doi: 10.1096/fj.202400446R

    Figure Lengend Snippet: Excess of sMSLN prevents cell clustering. (A) Schema showing method used to produce MSLN‐containing CM. Mock cells underwent transient transfection with Cas9 vector like MSLN KO cells, but no gRNA was included, so they retain endogenous MSLN expression (MSLN+). Transduction of KO cells with full‐length MSLN WT or Y318A expression construct produces the KO+WT and KO+Mu cell lines which overexpress MSLN (MSLN++). (B) ELISA to assess MSLN concentration of CM from equal numbers of cells plated for each type. (C) Cells were tagged with CellTracker dye then plated at equal density onto low adherence plates for 24 h before visualization by fluorescence microscopy. Representative images of multiple replicates with 4–8 fields imaged per replicate. (D) Schema for treatment of KLM1 and T3M4 KO cells with CM prior to RNA harvest. (E) PCA plots following RNA deep‐sequencing of CM‐treated KO cells. (F) Quantitation and directionality of GSEA pathway changes in KO cells treated with KO CM (negative control) as compared to MSLN‐containing CMs.

    Article Snippet: The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Techniques: Transfection, Plasmid Preparation, Expressing, Transduction, Construct, Enzyme-linked Immunosorbent Assay, Concentration Assay, Fluorescence, Microscopy, Sequencing, Quantitation Assay, Negative Control

    Soluble MSLN exposure results in release of IL‐1α. (A, B) Venn diagrams outlining GSEA pathway changes that occur when MSLN KO cells are exposed to sMSLN‐containing CM as compared with exposure to CM from MSLN KO cells. Pathways with statistically significant differential expression are listed. Those in bold were significantly changed in both KLM1 and T3M4. (C, D) KO cells were treated with stock CM isolated from KO, Mock, +WT or +Mu cells for 0 or 4 h, ** p < .01; **** p < .0001; ns, not significant. The concentration of IL‐1α (C) or LIF (D) in CM was then measured by ELISA.

    Journal: The FASEB Journal

    Article Title: Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization

    doi: 10.1096/fj.202400446R

    Figure Lengend Snippet: Soluble MSLN exposure results in release of IL‐1α. (A, B) Venn diagrams outlining GSEA pathway changes that occur when MSLN KO cells are exposed to sMSLN‐containing CM as compared with exposure to CM from MSLN KO cells. Pathways with statistically significant differential expression are listed. Those in bold were significantly changed in both KLM1 and T3M4. (C, D) KO cells were treated with stock CM isolated from KO, Mock, +WT or +Mu cells for 0 or 4 h, ** p < .01; **** p < .0001; ns, not significant. The concentration of IL‐1α (C) or LIF (D) in CM was then measured by ELISA.

    Article Snippet: The following primary and secondary antibodies were used for MSLN: Mouse‐human MSLN (BioXCell) and Goat Anti‐Mouse IgG (H+L)‐HRP Conjugate (Bio‐Rad, #1706516); for GAPDH: GAPDH (Cell Signaling, Cat#:5147) and Goat Anti‐Rabbit IgG (H+L)‐HRP Conjugate (Bio‐Rad; #1706515).

    Techniques: Quantitative Proteomics, Isolation, Concentration Assay, Enzyme-linked Immunosorbent Assay

    Immunohistochemical and Immunofluorescence analysis of MSLN and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x

    Journal: BMC Medicine

    Article Title: Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

    doi: 10.1186/s12916-024-03625-3

    Figure Lengend Snippet: Immunohistochemical and Immunofluorescence analysis of MSLN and NCL expression in TNBC tissue samples. a Immunohistochemistry (IHC) demonstrates the variability of MSLN and NCL expression across TNBC tissues categorized into four groups: MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High . The scale bar equals 200 µm, with original magnification at 10x. b Graph illustrating the percentage distribution of MSLN and NCL expression among 149 TNBC cases. c Kaplan–Meier survival plots contrasting the outcomes associated with different expression patterns of MSLN and NCL in TNBC patients. d Dual-color immunofluorescence staining identifying MSLN and NCL expressions within TNBC tissues (MSLN − /NCL Low , MSLN − /NCL High , MSLN + /NCL Low , and MSLN + /NCL High ). MSLN is marked with red fluorescence, NCL with green fluorescence, and nuclei are labeled with DAPI emitting blue fluorescence. The scale bar equals 50 µm, with original magnification at 63x

    Article Snippet: The membranes were blocked using 5% skim milk diluted in 0.1% Tween 20 in 1X Tris-buffered saline (TBST) for 1 h. The membranes were then incubated with primary antibodies: 1:500 dilution of mouse anti-human MSLN monoclonal antibody (sc-271540, Santa Cruz Biotechnology Inc), 1:500 dilution of rabbit anti-human NCL monoclonal antibody (14,574, Cell Signaling Technology Inc, Beverly, MA 1:5,000 dilution of mouse anti-human β-actin monoclonal antibody (sc-47778, Santa Cruz Biotechnology Inc) as an internal control.

    Techniques: Immunohistochemical staining, Immunofluorescence, Expressing, Immunohistochemistry, Staining, Fluorescence, Labeling

    The correlation between MSLN and NCL expressions in TNBC patients and the clinicopathological features

    Journal: BMC Medicine

    Article Title: Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

    doi: 10.1186/s12916-024-03625-3

    Figure Lengend Snippet: The correlation between MSLN and NCL expressions in TNBC patients and the clinicopathological features

    Article Snippet: The membranes were blocked using 5% skim milk diluted in 0.1% Tween 20 in 1X Tris-buffered saline (TBST) for 1 h. The membranes were then incubated with primary antibodies: 1:500 dilution of mouse anti-human MSLN monoclonal antibody (sc-271540, Santa Cruz Biotechnology Inc), 1:500 dilution of rabbit anti-human NCL monoclonal antibody (14,574, Cell Signaling Technology Inc, Beverly, MA 1:5,000 dilution of mouse anti-human β-actin monoclonal antibody (sc-47778, Santa Cruz Biotechnology Inc) as an internal control.

    Techniques:

    Analysis of peptide-HLA binding and generation of MSLN/NCL-specific T cells. a Molecular dynamics (MD) simulations illustrate the interaction between HLA-A*02 and the peptides pM-01, pM-02, pN-01, and pN-02, respectively. b Assessment of T2 cell binding to pM-01 and pM-02, and c pN-01 and pN-02 peptides at concentrations of 0, 12.5, 25, and 50 µM. d Evaluation of IFN-γ production by antigen-specific T cells in reaction to the respective peptides, as determined using the ELISpot assay. A representative ELISpot well image from three independent experiments is shown. e–g Quantitative analysis of the number of IFN-γ spots produced by T cells from healthy donors (HD-01, HD-02, and HD-03) in response to peptide stimulation. * P -value < 0.05 denotes statistical significance compared to unpulsed T cells. # P -value < 0.05 indicates significance compared to the control. @ P -value < 0.05 represents statistical significance observed between day 0 and day 9. HD, healthy donor; pM-01, MSLN peptide number 1; pM-02, MSLN peptide number 2; pN-01, NCL peptide number 1; pN-02, NCL peptide number 2

    Journal: BMC Medicine

    Article Title: Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

    doi: 10.1186/s12916-024-03625-3

    Figure Lengend Snippet: Analysis of peptide-HLA binding and generation of MSLN/NCL-specific T cells. a Molecular dynamics (MD) simulations illustrate the interaction between HLA-A*02 and the peptides pM-01, pM-02, pN-01, and pN-02, respectively. b Assessment of T2 cell binding to pM-01 and pM-02, and c pN-01 and pN-02 peptides at concentrations of 0, 12.5, 25, and 50 µM. d Evaluation of IFN-γ production by antigen-specific T cells in reaction to the respective peptides, as determined using the ELISpot assay. A representative ELISpot well image from three independent experiments is shown. e–g Quantitative analysis of the number of IFN-γ spots produced by T cells from healthy donors (HD-01, HD-02, and HD-03) in response to peptide stimulation. * P -value < 0.05 denotes statistical significance compared to unpulsed T cells. # P -value < 0.05 indicates significance compared to the control. @ P -value < 0.05 represents statistical significance observed between day 0 and day 9. HD, healthy donor; pM-01, MSLN peptide number 1; pM-02, MSLN peptide number 2; pN-01, NCL peptide number 1; pN-02, NCL peptide number 2

    Article Snippet: The membranes were blocked using 5% skim milk diluted in 0.1% Tween 20 in 1X Tris-buffered saline (TBST) for 1 h. The membranes were then incubated with primary antibodies: 1:500 dilution of mouse anti-human MSLN monoclonal antibody (sc-271540, Santa Cruz Biotechnology Inc), 1:500 dilution of rabbit anti-human NCL monoclonal antibody (14,574, Cell Signaling Technology Inc, Beverly, MA 1:5,000 dilution of mouse anti-human β-actin monoclonal antibody (sc-47778, Santa Cruz Biotechnology Inc) as an internal control.

    Techniques: Binding Assay, Enzyme-linked Immunospot, Produced, Control

    Characterization of MSLN and NCL peptides restricted to HLA-A*02:01

    Journal: BMC Medicine

    Article Title: Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

    doi: 10.1186/s12916-024-03625-3

    Figure Lengend Snippet: Characterization of MSLN and NCL peptides restricted to HLA-A*02:01

    Article Snippet: The membranes were blocked using 5% skim milk diluted in 0.1% Tween 20 in 1X Tris-buffered saline (TBST) for 1 h. The membranes were then incubated with primary antibodies: 1:500 dilution of mouse anti-human MSLN monoclonal antibody (sc-271540, Santa Cruz Biotechnology Inc), 1:500 dilution of rabbit anti-human NCL monoclonal antibody (14,574, Cell Signaling Technology Inc, Beverly, MA 1:5,000 dilution of mouse anti-human β-actin monoclonal antibody (sc-47778, Santa Cruz Biotechnology Inc) as an internal control.

    Techniques:

    Characterization of MSLN-specific, NCL-specific, and MSLN/NCL-specific T cells in healthy donors (HDs). a-c Demonstrates the percentages of CD3 + /CD4 + and CD3 + /CD8 + T cells in healthy donors: HD-01, HD-02, and HD-03, following a specified gating strategy. d-i Show the distribution of naive, central memory (T CM ), effector memory (T EM ), and T EMRA subpopulations within d-f CD3 + /CD4 + and g-i CD3 + /CD8 + T-cell compartments. j The frequencies of CD3 + /CD4 + /CD69 + and k of CD3 + /CD8 + /CD69 + T cell derived specific T cells after three cycle restimulation. Data were pooled from HD-01 to -03 and analyzed using one-way ANOVA and presented as mean ± SD of three independent experiments. Statistical significance is denoted by * P -value < 0.05 and # P -value < 0.05 when compared to unpulsed T cells. HD, healthy donor; pM-01, mesothelin peptide number 1; pM-02, mesothelin peptide number 2; pN-01, nucleolin peptide number 1; and pN-02, nucleolin peptide number 2

    Journal: BMC Medicine

    Article Title: Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

    doi: 10.1186/s12916-024-03625-3

    Figure Lengend Snippet: Characterization of MSLN-specific, NCL-specific, and MSLN/NCL-specific T cells in healthy donors (HDs). a-c Demonstrates the percentages of CD3 + /CD4 + and CD3 + /CD8 + T cells in healthy donors: HD-01, HD-02, and HD-03, following a specified gating strategy. d-i Show the distribution of naive, central memory (T CM ), effector memory (T EM ), and T EMRA subpopulations within d-f CD3 + /CD4 + and g-i CD3 + /CD8 + T-cell compartments. j The frequencies of CD3 + /CD4 + /CD69 + and k of CD3 + /CD8 + /CD69 + T cell derived specific T cells after three cycle restimulation. Data were pooled from HD-01 to -03 and analyzed using one-way ANOVA and presented as mean ± SD of three independent experiments. Statistical significance is denoted by * P -value < 0.05 and # P -value < 0.05 when compared to unpulsed T cells. HD, healthy donor; pM-01, mesothelin peptide number 1; pM-02, mesothelin peptide number 2; pN-01, nucleolin peptide number 1; and pN-02, nucleolin peptide number 2

    Article Snippet: The membranes were blocked using 5% skim milk diluted in 0.1% Tween 20 in 1X Tris-buffered saline (TBST) for 1 h. The membranes were then incubated with primary antibodies: 1:500 dilution of mouse anti-human MSLN monoclonal antibody (sc-271540, Santa Cruz Biotechnology Inc), 1:500 dilution of rabbit anti-human NCL monoclonal antibody (14,574, Cell Signaling Technology Inc, Beverly, MA 1:5,000 dilution of mouse anti-human β-actin monoclonal antibody (sc-47778, Santa Cruz Biotechnology Inc) as an internal control.

    Techniques: Derivative Assay

    Multiplex cytokine release profile by MSLN/NCL-specific T cells. Cytokine secretion analysis via a multiplex cytokine bead array conducted following a 24 h co-culture of MSLN/NCL-specific T cells with MSLN-overexpressing MDA-MB-231 (MSLN + /NCL + -M231) cell lines at an effector-to-target (E:T) ratio of 10:1. a-c Display the results from an individual experiment for each healthy donor (HD) and d pooled data of 3 HDs, showcasing the secretion profile of a comprehensive panel of 13 cytokines, including e IL-2, f IL-4, g IL-10, h IL-6, i IL-17A, j TNF-α, k sFas, l sFASL, m IFN-γ, n granzyme A, o granzyme B, p perforin, and q granulysin. r Provides a schematic diagram elucidating the process from in silico prediction of MSLN and NCL short peptides to the presentation of these peptides by antigen-presenting cells in PBMCs via MHC molecules to T lymphocytes, culminating in a cytotoxic response. Statistical significance is denoted by # P -value < 0.05 when compared to target cell (MSLN + /NCL + - M231) alone; @ P -value < 0.05 when compared to unpulsed T cells. HD, healthy donor; pM-01, MSLN peptide number 1; pM-02, MSLN peptide number 2; pN-01, NCL peptide number 1; pN-02, NCL peptide number 2

    Journal: BMC Medicine

    Article Title: Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells

    doi: 10.1186/s12916-024-03625-3

    Figure Lengend Snippet: Multiplex cytokine release profile by MSLN/NCL-specific T cells. Cytokine secretion analysis via a multiplex cytokine bead array conducted following a 24 h co-culture of MSLN/NCL-specific T cells with MSLN-overexpressing MDA-MB-231 (MSLN + /NCL + -M231) cell lines at an effector-to-target (E:T) ratio of 10:1. a-c Display the results from an individual experiment for each healthy donor (HD) and d pooled data of 3 HDs, showcasing the secretion profile of a comprehensive panel of 13 cytokines, including e IL-2, f IL-4, g IL-10, h IL-6, i IL-17A, j TNF-α, k sFas, l sFASL, m IFN-γ, n granzyme A, o granzyme B, p perforin, and q granulysin. r Provides a schematic diagram elucidating the process from in silico prediction of MSLN and NCL short peptides to the presentation of these peptides by antigen-presenting cells in PBMCs via MHC molecules to T lymphocytes, culminating in a cytotoxic response. Statistical significance is denoted by # P -value < 0.05 when compared to target cell (MSLN + /NCL + - M231) alone; @ P -value < 0.05 when compared to unpulsed T cells. HD, healthy donor; pM-01, MSLN peptide number 1; pM-02, MSLN peptide number 2; pN-01, NCL peptide number 1; pN-02, NCL peptide number 2

    Article Snippet: The membranes were blocked using 5% skim milk diluted in 0.1% Tween 20 in 1X Tris-buffered saline (TBST) for 1 h. The membranes were then incubated with primary antibodies: 1:500 dilution of mouse anti-human MSLN monoclonal antibody (sc-271540, Santa Cruz Biotechnology Inc), 1:500 dilution of rabbit anti-human NCL monoclonal antibody (14,574, Cell Signaling Technology Inc, Beverly, MA 1:5,000 dilution of mouse anti-human β-actin monoclonal antibody (sc-47778, Santa Cruz Biotechnology Inc) as an internal control.

    Techniques: Multiplex Assay, Co-Culture Assay, In Silico